<DOC>
	<DOCNO>NCT02183025</DOCNO>
	<brief_summary>To access efficacy safety Meloxicam 7.5 mg 15 mg daily compare Mefenamic acid 500 mg t.i.d . treatment period 3-5 day , observation period 3 menstrual cycle , symptomatic relief primary dysmenorrhea</brief_summary>
	<brief_title>Efficacy Safety Study Meloxicam Versus Mefenamic Acid Patients With Dysmenorrhea</brief_title>
	<detailed_description />
	<mesh_term>Dysmenorrhea</mesh_term>
	<mesh_term>Meloxicam</mesh_term>
	<mesh_term>Mefenamic Acid</mesh_term>
	<criteria>Female patient 18 40 year Patients experience primary ( functional ) dysmenorrhea last 3 consecutive menstrual period . Diagnosis base symptom clinical sign : abdominopelvic pain , may radiate back along thigh ; systemic symptom include nausea , vomit , diarrhoea , headache , fatigue , nervousness , dizziness ; symptomatology usually hour one day commencement visible vaginal bleeding Evaluation lumbar and/or abdominopelvic pain due dysmenorrhea &gt; 35 mm 100 mm visual analogue scale ( VAS ) Outpatients Patients grant write informed consent Therapy NSAID ( nonsteroidal antiinflammatory drug ) require recommended Known suspect hypersensitivity trial drug excipients , analgesic , antipyretic NASIDs Analgesic concomitant treatment ( cycle paracetamol administration allow ) To initiate hormonal contraception intrauterine device inclusion trial last 3 month Abdominal surgery pelvic procedure schedule study Patients organic dysmenorrhea ( endometriosis , salpingitis , adnexitis , uterine retroversion , tubal cyst , ovarian cyst , pathological vaginal secretion , painful pelvic exploration , etc . ) Patients neoplastic disorder History recent abdominal pelvic trauma require surgery Peptic ulcer within past 6 month Pregnancy breast feed Asthma , nasal polyp , angioneurotic edema rash follow aspirin NSAIDs administration Concomitant treatment anticoagulant , include heparin aspirin , lithium methotrexate Concomitant administration NSAIDs ( include aspirin &gt; 150 mg daily ) analgesic Confinement bed rest Administration NSAID two day ( three oxicams ) first administration trial drug Present treatment treatment within last two month corticosteroid Impaired renal function ( serum urea &gt; 125 % upper limit normal range ; serum creatinine &gt; 150 % upper limit normal range ) Sever liver injury ( alanine amino transferase ALAT &gt; 2 x upper normal range limit aspartate amino transferase ASAT &gt; 2 x upper normal range limit ) Hematological disorder ( platelet count &lt; 100,000/mm**3 , leucocyte count &lt; 3,000/mm**3 ) Participation another clinical trial study previous month Previous participation trial Patient unable comply protocol Bleeding disorder</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>